EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Differential Effects of Zanubrutinib and Ibrutinib on Neutrophil Antifungal Functions: Insights from Live-Cell Imaging

Benoit S. Marteyn, Aymeric Silvin, Tamou Thahouly, Nathan Broussaudier, Jean-Daniel Fauny, Marina Valente Barroso, Thierry Fontaine, Kamel Laribi, David Ghez

Journal of Innate Immunity · 2026-08-14 · 18 (1) · 448-460

DOI: 10.1159/jin/adhag001 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Bruton tyrosine kinase inhibitors (BTKi) impair anti-Aspergillus immune responses and increase the risk of invasive fungal infections (IFI). More selective second-generation BTKi have fewer off-target effects thus a better tolerance than ibrutinib. Though clinical data suggest the incidence of IFI is lower with second-generation BTKi, whether they have less impact on antifungal immunity remains unclear. Methods: We studied the activation phenotype and behavior of human neutrophils in vitro with fungal extracts or living Aspergillus fumigatus in the presence of either ibrutinib or zanubrutinib, a more selective second-generation BTKi, using various approaches, including live microscopy. Results: Both molecules inhibited the activation-induced phenotypic changes in neutrophils following exposure to hyphae. Similarly, ibrutinib and zanubrutinib impaired neutrophil-mediated inhibition of conidia germination. By contrast, live neutrophil imaging showed that neutrophils exposed to ibrutinib but not zanubrutinib kept a round morphology, suggesting a defective activation, were less mobile, and showed impaired conidia phagocytosis. Conclusion: We confirm here that ibrutinib and zanubrutinib inhibit neutrophil antifungal activity, strongly suggesting that BTK plays a central role. However, subtle differences between ibrutinib and zanubrutinib were evidenced using live microscopy, which might indicate additional off-target effects, and potentially partially explain the lower incidence of IFI with zanubrutinib; the clinical relevance remains to be determined.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →